Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

We assessed the tolerability, pharmacodynamics as measured by inhibition of platelet aggregation (IPA), and pharmacokinetics of prasugrel (CS-747, LY640315), a novel thienopyridine antiplatelet agent in healthy volunteers. Twenty-four subjects were randomized into four groups of six in a double-blin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Platelets (Edinburgh) 2006-06, Vol.17 (4), p.209-217
Hauptverfasser:	Asai, Fumitoshi, Jakubowski, Joseph A., Naganuma, Hideo, Brandt, John T., Matsushima, Nobuko, Hirota, Takashi, Freestone, Stephen, Winters, Kenneth J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Diphosphate - pharmacology Administration, Oral Adolescent Adult CS-747 Dose-Response Relationship, Drug Double-Blind Method Female Humans Male Middle Aged phase 1 Piperazines - administration & dosage Piperazines - blood Piperazines - pharmacokinetics Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - blood Platelet Aggregation Inhibitors - pharmacokinetics platelets Prasugrel Prasugrel Hydrochloride Purinergic P2 Receptor Antagonists Receptors, Purinergic P2Y12 thienopyridine Thiophenes - administration & dosage Thiophenes - blood Thiophenes - pharmacokinetics Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!